The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up

OBJECTIVE To describe metastasis-free survival (MFS) in men with prostate-specifi c antigen (PSA) recurrence following radical prostatectomy, and to defi ne clinical prognostic factors modifying metastatic risk. PATIENTS AND METHODS We conducted a retrospective analysis of 450 men treated with prostatectomy at a tertiary hospital between July 1981 and July 2010 who developed PSA recurrence (= 0.2 ng/ mL) and never received adjuvant or salvage therapy before the development of metastatic disease. We estimated MFS using the Kaplan Meier method, and investigated factors infl uencing the risk of metastasis using Cox proportional hazards regression. RESULTS Median follow-up after prostatectomy was 8.0 years, and after biochemical recurrence was 4.0 years. At last follow-up, 134 of 450 patients (29.8%) had developed metastases, while median MFS was 10.0 years. Using multivariable regressions, two variables emerged as independently predictive of MFS: PSA doubling time (< 3.0 vs 3.0 -8.9 vs 9.0 -14.9 vs = 15.0 months) and Gleason score (= 6 vs 7 vs 8 -10). Using these stratifi cations of Gleason score and PSA doubling time, tables were constructed to predict median, 5-and 10-year MFS after PSA recurrence. In different patient subsets, median MFS ranged from 1 to 15 years. CONCLUSIONS In men undergoing prostatectomy, MFS after PSA recurrence is variable and is most strongly infl uenced by PSA doubling time and Gleason score. These parameters serve to stratify men into different risk groups with respect to metastatic progression. Our fi ndings may provide the background for appropriate selection of patients, treatments and endpoints for clinical trials.